To enact section 4729.44 of the Revised Code to authorize the dispensing of ivermectin without a prescription.
SB 249 would create a new section of Ohio law allowing pharmacists, and supervised pharmacy interns, to dispense ivermectin without a prescription to adults age 18 and older. The bill does not make ivermectin over-the-counter in an unrestricted sense; instead, dispensing must occur under a protocol established by a prescriber and in accordance with rules adopted by the State Board of Pharmacy. The protocol must include a screening risk assessment tool, a standardized fact sheet covering indications, contraindications, proper use, and the importance of follow-up with a prescriber, and a requirement to dispense the drug or refer the individual to a pharmacy that can do so as soon as practical.
The bill also permits a pharmacist to charge an administrative fee for the service, requires notification to the patient’s primary care provider when known, and preserves existing authority to fill or refill ivermectin prescriptions. It provides liability and disciplinary protections for pharmacists, pharmacy interns, and prescribers acting in good faith, limiting civil liability to cases of gross negligence or willful misconduct. The State Board of Pharmacy, in consultation with the State Medical Board and Board of Nursing, would be required to adopt implementing rules that set minimum protocol standards.
The bill’s impact on state law would be to add a new pharmacist-access pathway for ivermectin, changing how the drug may be obtained in Ohio and expanding pharmacist authority under Chapter 4729 of the Revised Code. It would affect pharmacists, pharmacy interns, prescribers who establish protocols, adult consumers seeking ivermectin, and the state licensing boards responsible for rulemaking and oversight. It would also create a new framework for documentation, counseling, and interprofessional communication around dispensing.
The general sentiment reflected by the bill text is permissive and access-oriented, with the sponsors seeking to make ivermectin easier to obtain while still retaining professional oversight and safety checks. Because there are no committee transcripts or recorded votes provided, there is no documented public debate in the supplied materials, but the structure of the bill suggests an attempt to balance access with safeguards and liability limits.
The main point of contention likely centers on whether ivermectin should be available without a prescription at all, and under what clinical or regulatory conditions. Supporters would likely emphasize consumer access, pharmacist discretion, and reduced barriers, while critics may raise concerns about medical appropriateness, self-medication, and the adequacy of pharmacist screening and counseling. The liability protections and the role of prescriber-established protocols may also be debated as either necessary safeguards or insufficient oversight.
SB 249 would amend Ohio’s pharmacy law by enacting section 4729.44 of the Revised Code to authorize pharmacist- and pharmacy-intern dispensing of ivermectin without a prescription under a regulated protocol. It would require rulemaking by the State Board of Pharmacy, in consultation with the State Medical Board and Board of Nursing, and would create new duties for screening, counseling, referral, and provider notification, while also granting limited immunity from criminal, disciplinary, and civil liability for good-faith actions.
Based on the bill’s text, the measure appears generally supportive of expanded access to ivermectin while preserving professional oversight, suggesting a pro-access but regulated approach. No committee transcript or vote history was provided, so there is no recorded evidence here of opposition or support from legislators beyond the sponsors and cosponsors listed.
The likely controversy is whether ivermectin should be dispensed without a prescription and whether pharmacists should serve as the gatekeepers for that access. Supporters are likely to favor convenience, access, and pharmacist-led screening, while opponents may question safety, medical necessity, and the risk of inappropriate use. Additional debate may focus on the scope of liability protections, the adequacy of the required protocol and fact sheet, and whether the bill could encourage use of ivermectin outside established clinical guidance.